Clinical Trials Browser

Phase 1/2 × Has results × onvansertib × Clear all

NCT03829410 2025-03-04

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Phase 1/2 Completed

68 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT03303339 2023-02-27

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

72 enrolled 31 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute